Avalo Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
Item 16. 10-K Summary.
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Avalo Therapeutics, Inc.
/s/ Christopher Sullivan
Christopher Sullivan
Chief Financial Officer
Date: March 20, 2025
Pursuant to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Garry Neil, M.D. | President and Chief Executive Officer, Chairman of the Board of Directors and Director | March 20, 2025 |
| Garry Neil, M.D. | (Principal Executive Officer) | |
| /s/ Christopher Sullivan | Chief Financial Officer | March 20, 2025 |
| Christopher Sullivan | (Principal Financial and Accounting Officer) | |
| /s/ June Almenoff, M.D., Ph.D. | Director | March 20, 2025 |
| June Almenoff, M.D., Ph.D. | ||
| /s/ Mitchell Chan | Director | March 20, 2025 |
| Mitchell Chan | ||
| /s/ Jonathan Goldman, M.D. | Director | March 20, 2025 |
| Jonathan Goldman, M.D. | ||
| /s/ Aaron Kantoff | Director | March 20, 2025 |
| Aaron Kantoff | ||
| /s/ Gilla Kaplan, Ph.D. | Director | March 20, 2025 |
| Gilla Kaplan, Ph.D. | ||
| /s/ Samantha Truex | Director | March 20, 2025 |
| Samantha Truex | ||
AVALO THERAPEUTICS, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Mezzanine and Stockholders’ Equity for the years ended December 31, 2024 and 2023 | F-6 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 | F-8 |
| Notes to Consolidated Financial Statements | F-11 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.